ライフサイエンスコーパス: pg

1 sitivity with limit of detection down to 1.0 pg/mL, which is 4 orders magnitude lower than NSE cut-of

2 pg/ml [39.2, 119.4]; p = .003), IL-15 (12.0 pg/ml [12.0, 12.0] vs 12.0 pg/ml [12.0, 126.7]; p = .03)

3 003), IL-15 (12.0 pg/ml [12.0, 12.0] vs 12.0 pg/ml [12.0, 126.7]; p = .03), and IFN-alpha (5.1 pg/mL

4 3 pg/ml [30.7, 344.4]; p = .001), IL-8 (32.0 pg/ml [5.6, 53.1] vs 59.1 pg/ml [39.2, 119.4]; p = .003)

5 icrowell ELISA plate assay, the LoD was 42.0 pg mL(-1) and the linear range was 1.60-100 ng mL(-1).

6 .0 ng/ml increment in CML and a 22.1 +/- 6.0 pg/ml increment in sRAGE (P < 0.0001 for both).

7 ular endothelial growth factor (VEGF) (880.0 pg/mL vs 245.4 pg/mL; P = .012) and decreased monocyte c

8 elative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial.

9 NT-proBNP (50-10,000 pg/mL), cTnI (1-10,000 pg/mL), and fibrinogen (0.1-5 mg/mL).

10 for CRP (0.1-50 mg/L), NT-proBNP (50-10,000 pg/mL), cTnI (1-10,000 pg/mL), and fibrinogen (0.1-5 mg/

11 ction (LODs) in the range of 3,000 to 10,000 pg/ul would provide ideal sensitivity and specificity fo

12 pg (small pseudodiploid cell) to over 4,000 pg, with a resolution ranging from ~1% to ~0.05%.

13 the Mo2 repeat can detect as little as 0.01 pg.

14 both methods could detect Tpm as low as 0.01 pg/mL.

15 ssue) and NPs from patients with AERD (61.03 pg/mg of tissue) compared to inferior turbinate tissue f

16 00 pg/mL with a low detection limit of 0.036 pg/mL.

17 roBNP levels by 0.3 pg/mL (CI, -0.5 to -0.04 pg/mL).

18 of 16S rRNA and katG mRNA generated from 0.1 pg and 10 pg total RNA taken for NASBA, respectively, in

19 with Polynorepinephrine pNE-modified is 0.1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 1.91 pg mL(-1)), and 1

20 -1) to 200 ng mL(-1) (limit of detection 0.1 pg mL(-1)), respectively.

21 Mp419 repeat has a limit of detection of 0.1 pg, equivalent of 1/1000(th) of a microfilaria, while th

22 of the sensors varied in the range from 0.1 pg/ml to 10 mug/ml resulting in a change of the surface

23 proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.1 pg/mL).

24 (23.5 pg cm(-2) yr(-1)) and Kongsvegen (14.1 pg cm(-2) yr(-1)).

25 , we also detect the cDNA from SARS-CoV-2 (1 pg) with high specificity against SARS-CoV (2003).

26 , and IFN-alpha (5.1 pg/mL [5.1, 5.1] vs 5.1 pg/ml [5.1, 26.3]; p = .04).

27 [12.0, 126.7]; p = .03), and IFN-alpha (5.1 pg/mL [5.1, 5.1] vs 5.1 pg/ml [5.1, 26.3]; p = .04).

28 .001), IL-8 (32.0 pg/ml [5.6, 53.1] vs 59.1 pg/ml [39.2, 119.4]; p = .003), IL-15 (12.0 pg/ml [12.0,

29 s nontransplant GNB: IL-2 (median [IQR]: 7.1 pg/ml [7.1, 7.1] vs 32.6 pg/ml [7.1, 88.0]; p = .001), M

30 (11,396.0 +/- 3,457.7 vs 8,118.2 +/- 2,795.1 pg/mL, p < 0.05).

31 10(5) pg mL(-1) (LOD: 1.91 pg mL(-1)), and 1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 0.70 pg mL(-1)) with P

32 S-based muPAD was identified at 8, 10, and 1 pg mL(-1), for GPBB, CK-MB and cTnT, respectively, which

33 ed detections showed linear responses from 1 pg mL(-1) to 300 ng mL(-1) (limit of detection 0.2 pg mL

34 provides a wide linear response range from 1 pg/mL to 100 ng/mL (5 orders) and an extremely low limit

35 A high sensitivity of 1 pg/mL ZIKV, desirable specificity, data storage, and geo

36 ventually achieved a limit of detection of 1 pg/mL.

37 The sensor has a detection limit of ~1 pg/mL and provides results in less than five minutes fro

38 io for exacerbation increased 10% for each 1-pg/mul increase in baseline IL-6 level.

39 8 fg/mL and a linear dynamic range of 0.1-10 pg/mL using a minimal sample volume (20 muL) and with a

40 he Arctic (260 +/- 20 pg/L versus 190 +/- 10 pg/L).

41 tection (LOD) was 2 pg mL(-1) for CEA and 10 pg mL(-1) for NSE.

42 A and katG mRNA generated from 0.1 pg and 10 pg total RNA taken for NASBA, respectively, in less than

43 chemistry enables low detection limits of 10 pg mL(-1) or better for all protein biomarkers, while mi

44 >100 and detection limits on the order of 10 pg.

45 ing serum parathyroid hormone (OR 1.1 per 10 pg/mL 95% CI 1.05-1.13), and endocrinologist evaluation

46 4, 1.60 per mg/dL; 1.14-2.23 and 0.82 per 10 pg/mL; 0.68-0.99, respectively).

47 g an extremely low DNA input requirement (10 pg per library).

48 gh selectivity at detection limits of sub-10 pg/mL in 25% serum (by volume in PBS).

49 hospitalization within 12 months, BNP >=100 pg/mL or NT-proBNP >=400 pg/mL).

50 erminal pro-B-type natriuretic peptide) <100 pg/mL), and those with ECG-LVH and abnormal levels of ei

51 imit of 100 pg/ml and a dynamic range of 100 pg/ml - 100 ng/ml in human saliva.

52 DUI test with a lower detection limit of 100 pg/ml and a dynamic range of 100 pg/ml - 100 ng/ml in hu

53 cholerae toxin at improved sensitivity (100 pg/ml) in comparison to optical enzyme-linked immunosorb

54 L(-1), with a wide linear range of 2 to 1000 pg mL(-1), while for CD81, the limit of detection was 3

55 301-872)) than presymptomatic carriers (1003 pg/mL (624-1358), p<0.001) and non-carriers (990 pg/mL (

56 The limit of detection attained is 2.11 pg mL(-1) and displays high stability whereby it retains

57 oBNP with dapagliflozin versus placebo (1133 pg/dL (95% CI 1036-1238) vs 1191 pg/dL (95% CI 1089-1304

58 acebo (1133 pg/dL (95% CI 1036-1238) vs 1191 pg/dL (95% CI 1089-1304), P=0.43).

59 day after first RFA and to 137.26 +/- 107.12 pg/ml at 1 day after second RFA.

60 YY, CD 236 +/- 16 pg/mL versus HV 118 +/- 12 pg/mL (P <= 0.0001)].

61 of perfluorooctanoate (PFOA) (median of 120 pg/mL of ww in males and 150 pg/mL of ww in females) and

62 els at 2 AM were 150 pg/mL (range, 125-2,125 pg/mL) in the melatonin group and 32.5 pg/mL (range, 18.

63 6.15%; full profiles were generated with 125 pg DNA (95.12% of alleles at 62 pg),; and we found 100%

64 to 1531 pg/mL) in the digoxin group vs 1250 pg/mL (interquartile range, 847 to 1890 pg/mL) in the bi

65 Median (Q1-Q3) levels of NT-proBNP were 1286 pg/mL (778-2072) in those with AF and 288 pg/mL (122-704

66 .2 pg/m(3) at Eagle Harbor, Michigan to 1320 pg/m(3) at Cleveland, Ohio.

67 of cytokine storm (interleukin-6 median, 135 pg/mL) and macrophage activation (D-dimer median, 5284 n

68 median of 1565 pg/mL of ww in males and 1370 pg/mL of ww in females) and perfluorotetradecanoate (PFT

69 pro-brain natriuretic peptide level was 1403 pg/mL; 761 (96.5%) completed the trial.

70 entiles, 9.6-20.4 ng/L), 811 pg/mL (386-1436 pg/mL), and 1661 pg/mL (1179-2427 pg/mL), respectively.

71 6.64 +/- 1021.72 pg/ml to 1388.13 +/- 890.15 pg/ml at 1 day after first RFA and to 137.26 +/- 107.12

72 SA had a lower limit of quantification of 15 pg/mL LAM, corresponding to 121 colony-forming units (CF

73 rance after adjusting for age (log10 GDF-15 [pg/mL] [B, -54.3 (95% CI, -106 to -2.00), P=0.043], log1

74 drug reaching on average values of about 150 pg/muPL, for both CURC and DEX.

75 (median of 120 pg/mL of ww in males and 150 pg/mL of ww in females) and perfluorohexanesulfonate (PF

76 and elevated natriuretic peptides: BNP >=150 pg/mL or NT-proBNP >=600 pg/mL (for patients with HF hos

77 Melatonin serum peak levels at 2 AM were 150 pg/mL (range, 125-2,125 pg/mL) in the melatonin group an

78 960 pg/mL (interquartile range, 626 to 1531 pg/mL) in the digoxin group vs 1250 pg/mL (interquartile

79 erfluorononadecanoate (PFNA) (median of 1565 pg/mL of ww in males and 1370 pg/mL of ww in females) an

80 /- 3 ug/mL (P <= 0.0001); PYY, CD 236 +/- 16 pg/mL versus HV 118 +/- 12 pg/mL (P <= 0.0001)].

81 XCL10) concentrations changed by mean = -160 pg/mL per day at 24 hours, but no further after Day 4.

82 ng/L), 811 pg/mL (386-1436 pg/mL), and 1661 pg/mL (1179-2427 pg/mL), respectively.

83 chemokine (C-X-C motif) ligand 1 (1903+/-168 pg/mL versus 1272+/-177 pg/mL; P=0.01) concentrations an

84 (cardiopulmonary resuscitation, 426 +/- 169 pg/mL; extracorporeal cardiopulmonary resuscitation, 240

85 nferior turbinate tissue from controls (7.17 pg/mg of tissue [P < .001]).

86 ligand 1 (1903+/-168 pg/mL versus 1272+/-177 pg/mL; P=0.01) concentrations and classic CD14(++)CD16(-

87 1250 pg/mL (interquartile range, 847 to 1890 pg/mL) in the bisoprolol group (ratio of geometric means

88 nverters than in non-converting carriers (19 pg/mL [17-28] vs 8 pg/mL [6-11]; p=0.0007; adjusted for

89 vated in hospitalized patients (3233 vs 1930 pg/mL, P < .0001).

90 -1) to 300 ng mL(-1) (limit of detection 0.2 pg mL(-1)) and 5 pg mL(-1) to 200 ng mL(-1) (limit of de

91 en within 24 h (mean absolute difference 0.2 pg/ml; intraindividual variation below 0.1%).

92 was < 10% for high (942 pg/mL) and low (38.2 pg/mL) PTH concentration.

93 Prestress and stressor cTnT cutpoints of 4.2 pg/mL predicted 24-hour, daytime, and nighttime diastoli

94 OPE concentrations (EOPEs) ranged from 41.2 pg/m(3) at Eagle Harbor, Michigan to 1320 pg/m(3) at Cle

95 t SAB vs nontransplant SAB (mean [SD]: 750.2 pg/ml [194.6] vs 656.5 pg/ml [147.6]; p = .046).

96 84 pg/mL [216.8 to 318.9 pg/mL]) and 3 (87.2 pg/mL [75.2 to 97.8 pg/mL]).

97 The limit of detection (LOD) was 2 pg mL(-1) for CEA and 10 pg mL(-1) for NSE.

98 rth Atlantic entering the Arctic (260 +/- 20 pg/L versus 190 +/- 10 pg/L).

99 rasensitive toxin assay (clinical cutoff, 20 pg/mL).

100 82) (menses within 12 months; AMH level >=20 pg/mL; group 1), premenopausal with reduced ovarian rese

101 with reproductive aging milestones (AMH <20 pg/mL or >12 months of amenorrhea).

102 with a low constitutive IL-10 level (ie, <20 pg/mL); moreover, the Zostavax-induced FAMA and gpELISA

103 (n = 224) (menses within 12 months; AMH <20 pg/mL; group 2), or postmenopausal (n = 743) (no menses

104 n = 743) (no menses within12 months; AMH <20 pg/mL; group 3).

105 With a limit of detection of 20 pg mL(-1) (63 pM), the competitive ULISA is well applica

106 etection of 1 ng/mL cocaine in serum and 200 pg/mL caffeine in raw urine, as well as the differentiat

107 tectable protein concentration as low as 200 pg/mL for the plasmonic nanohole array and 1 ng/mL for t

108 ose with GDF-15 in the lowest quartile (<200 pg/mL) in the age- and sex-adjusted model.

109 nd diel cycles in oxidized mercury (0 to 200 pg m(-3)) and will be an important tool for future studi

110 ial dilutions of synthetic TNF-alpha (0-2000 pg mL(-1)) by plotting the area under the curve of the s

111 to 999 (reference), 1000 to 1999, and >=2000 pg/mL.

112 as + particle phase) ranging from 80 to 2030 pg/m(3).

113 study, median NT-proBNP levels rose from 21 pg/mL pre-lipopolysaccharide to 54 pg/mL post-lipopolysa

114 (median of 370 pg/mL of ww in males and 210 pg/mL of ww in females) showed the slowest rate of telom

115 (386-1436 pg/mL), and 1661 pg/mL (1179-2427 pg/mL), respectively.

116 the concentration range of 0.1 pM-10 nM (25 pg mL(-1) - 2500 ng mL(-1)) with a limit of detection (L

117 exhibited a wide linear range of 0.150-2500 pg/mL with a low detection limit of 0.036 pg/mL.

118 ation, 240 +/- 61 pg/mL; CO-E-CPR, 89 +/- 26 pg/mL; p < 0.05) and heme oxygenase-1 (sham, 1 +/- 0.1;

119 865.18 +/- 828.93 pg/ml to 145.72 +/- 119.27 pg/ml at 1 day after RFA and in group 2 from 2256.64 +/-

120 86 pg/mL (778-2072) in those with AF and 288 pg/mL (122-704) in those without ( P<0.001).

121 esults with high sensitivity, as low as 5.29 pg/mL, from only a small sample volume (4 muL).

122 .9 to -0.1 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.04 pg/mL).

123 .9 to -0.2 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.1 pg/mL).

124 adjusted mean difference from controls 192.3 pg/mL, 95% CI 126.5 to 445.6), but not in those with C9o

125 issues: 941.8 pg/g of 9,10-EpOME and 2,198.3 pg/g of 12,13-EpOME in fat body of a lepidopteran insect

126 MIP-1beta (30.7 pg/ml [30.7, 30.7] vs 243.3 pg/ml [30.7, 344.4]; p = .001), IL-8 (32.0 pg/ml [5.6, 5

127 h a detection limit of 44.5 pg mL(-1) & 41.3 pg mL(-1) for stx subtypes, respectively and showed low

128 control (69.9 +/- 9.6 pg/ml vs 25.4 +/- 5.3 pg/ml, p = 0.0001) and the serum levels of LIGHT were si

129 onocyte chemotactic protein-1 (MCP-1) (513.3 pg/mL vs 809.5 pg/mL; P = .0.042) concentrations compare

130 ents in group-1 (521.9 pg/mL [428.5 to 569.3 pg/mL]) (P <0.01) than groups 2 (234.84 pg/mL [216.8 to

131 /mL) versus the ASD group (1,663.6 +/- 587.3 pg/mL, p < 0.0001).

132 BPA showed the lowest concentrations (8.3 pg/g f.w.), far below those of phthalates (6431 pg/g f.w

133 uploidy in samples containing as little as 3 pg of DNA.

134 A limit of detection of 3 pg/muL of DNA, similar to the available qPCR kits, is ac

135 ms with a naked eye limit of detection of ~3 pg/mm(2), lower than industry standard sensors based on

136 while for CD81, the limit of detection was 3 pg mL(-1), with a wide linear range of 0.01 to 10 ng mL(

137 liable detection of TES antigen at 10 and 30 pg/mL level was demonstrated in phosphate buffered salin

138 better limits of detection and it reached 30 pg g(-1) with Ir modifier.

139 Baseline IL-6 greater than 30 pg/mL predicts IMV requirement in patients with COVID-19

140 IL-6 levels greater than 30 pg/mL was the best predictor for IMV (odds ratio, 7.1; P

141 ermeation rate was relatively high (up to 30 pg s(-1)), but the agreement decreased for lower permeat

142 B-type natriuretic peptide (NT-proBNP) >=300 pg/ml.

143 1.17, 5.03]; p = 0.02) and NT-proBNP (>=300 pg/mL; HR 2.28 [95% CI 1.24, 4.29]; p = 0.01).

144 /- 34 pg/ml; 0.8 to <1.2 g/kg/d, 1479 +/- 31 pg/ml; >=1.2 g/kg/d, 1574 +/- 47 pg/ml; P for trend < 0.

145 l) than for the other genotypes (mean: 2,317 pg/ml; p = 0.014), and patients with CXCL12 levels above

146 e detection limit for oxidized mercury of 33 pg m(-3).

147 AGE concentrations (<0.8 g/kg/d, 1412 +/- 34 pg/ml; 0.8 to <1.2 g/kg/d, 1479 +/- 31 pg/ml; >=1.2 g/kg

148 is showed that ST2 (>26 ng/mL), TNFR1 (>3441 pg/mL), and REG3alpha (>25 ng/mL) are associated with NR

149 latonin group and 32.5 pg/mL (range, 18.5-35 pg/mL) in the placebo group (p < 0.001).

150 GDF-15 values in the highest quartile (>=358 pg/mL) had an OR for VTE of 2.05 (95% confidence interva

151 ] pg/mL versus median, 2187 [IQR, 1344-3620] pg/mL, P<0.001).

152 fluorotetradecanoate (PFTeDA) (median of 370 pg/mL of ww in males and 210 pg/mL of ww in females) sho

153 plasma concentrations of soluble CD40L (376 pg/ml vs. 505 pg/ml, P = 0.001) compared with those with

154 (median of 495 pg/mL of ww in males and 395 pg/mL of ww in females) were positively associated with

155 Ws and achieve a low limit of detection (0.4 pg ml(-1)) in detecting p24 antigen as a marker for huma

156 the limit of detection for Claudin 7 was 0.4 pg mL(-1), with a wide linear range of 2 to 1000 pg mL(-

157 ullin (n = 2,003) was 66.6 pg/mL (34.6-136.4 pg/mL) and the median Simplified Acute Physiology Score

158 Detection limits of 3.5-19.4 pg of fluorine on-column are obtained using the reported

159 l growth factor (VEGF) (880.0 pg/mL vs 245.4 pg/mL; P = .012) and decreased monocyte chemotactic prot

160 5-fold lower atmospheric concentrations (3-4 pg.L(air)(-1)), while important foam accumulation was ob

161 ndomized 61 patients with elevated IL-6 (>=4 pg/ml) to receive placebo or ziltivekimab (doses of 2, 6

162 ral to the placenta was 54.8 (IQR 37.1-88.4) pg/mL (n = 11) and 23.7 (IQR -11; 70.5) pg/mL (n = 6) wh

163 buoyant mass of single cells ranging from 40 pg (small pseudodiploid cell) to over 4,000 pg, with a r

164 terminal pro-B-type natriuretic peptide [>40 pg/mL] or troponin T [>0.6 pg/mL]) were recruited, along

165 2 months, BNP >=100 pg/mL or NT-proBNP >=400 pg/mL).

166 patients without AF and with NT-proBNP <400 pg/mL are low.

167 an serum in a concentration range of 25-4000 pg/mL.

168 rimary end point (median, 1208 [IQR, 0-4305] pg/mL versus median, -86 [IQR, -322 to 491] pg/mL, P<0.0

169 nd LOQ for cytokine peptides was 130 and 433 pg/mL, respectively.

170 Plasma IL-10 concentration >45 pg/ml predicted mortality (HR, 4.21; 95% CI, 1.21-14.68;

171 interquartile range [IQR], 332-1822) and 455 pg/mL (IQR, 153-1090) at 12 months (difference, P < .001

172 01), higher discharge (1922 [IQR, 1045-4652] pg/ml vs 3372 [IQR, 1553-5452] pg/ml, respectively; P <

173 1479 +/- 31 pg/ml; >=1.2 g/kg/d, 1574 +/- 47 pg/ml; P for trend < 0.0001).

174 vs. 5.5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0.01), respectively.

175 The LoD was found to be 1.49 pg mL(-1) and the limit of quantification was 3.81 pg mL

176 pg/mL versus median, -86 [IQR, -322 to 491] pg/mL, P<0.001).

177 fluorohexanesulfonate (PFHxS) (median of 495 pg/mL of ww in males and 395 pg/mL of ww in females) wer

178 We observed a limit of detection of 0.5 pg/mL and a limit of quantitation of 5 pg/mL with virtua

179 gave limits of detection (LOD) as low as 0.5 pg/mL.

180 ogel particles (analytical sensitivity = 2.5 pg/mL) to study tick pathogen-specific proteins shed in

181 ype natriuretic peptide (7,424.5 vs. 3,209.5 pg/mL; P < 0.05).

182 achloroanisole (PCA) at Lomonosovfonna (23.5 pg cm(-2) yr(-1)) and Kongsvegen (14.1 pg cm(-2) yr(-1))

183 2,125 pg/mL) in the melatonin group and 32.5 pg/mL (range, 18.5-35 pg/mL) in the placebo group (p < 0

184 tin protein (ca. 64 million molecules or 4.5 pg per lymphocyte).

185 Serum interleukin-6 (23.1+/-4.5 pg/mL versus 6.5+/-5.8 pg/mL; P<0.001) and chemokine (C-

186 00 ng mL(-1), with a detection limit of 44.5 pg mL(-1) & 41.3 pg mL(-1) for stx subtypes, respectivel

187 SAB (mean [SD]: 750.2 pg/ml [194.6] vs 656.5 pg/ml [147.6]; p = .046).

188 a limit of detection (LOD) of 0.033 pM (7.5 pg mL(-1)) of MUC1.

189 ctic protein-1 (MCP-1) (513.3 pg/mL vs 809.5 pg/mL; P = .0.042) concentrations compared with nonrespo

190 -1) (limit of detection 0.2 pg mL(-1)) and 5 pg mL(-1) to 200 ng mL(-1) (limit of detection 0.1 pg mL

191 f 0.5 pg/mL and a limit of quantitation of 5 pg/mL with virtually no background signal.

192 formance in a linear range of 100 fg/mL to 5 pg/mL with a low detection limit of 75 fg/mL.

193 OD: 1.91 pg mL(-1)), and 1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 0.70 pg mL(-1)) with Polydopamine (pDA)

194 phrine pNE-modified is 0.1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 1.91 pg mL(-1)), and 1 pg mL(-1) - 10(5)

195 8.4) pg/mL (n = 11) and 23.7 (IQR -11; 70.5) pg/mL (n = 6) when the sample was contralateral.

196 ng(-1) mL, a dynamic response range from 50 pg mL(-1) to 100 ng mL(-1), with a detection limit of 44

197 concentration range close to zero (1.50-500 pg mL(-1)) following a method reported in literature.

198 in two concentration ranges from 1.50 to 500 pg mL(-1) and from 0.50 to 100 ng mL(-1).

199 e detected immunoreactive IL-27 (953 +/- 504 pg/mg lysate), a mediator not previously associated with

200 trations of soluble CD40L (376 pg/ml vs. 505 pg/ml, P = 0.001) compared with those without MLN enlarg

201 elevated in symptomatic carriers (median 52 pg/mL [IQR 24-69]) compared with presymptomatic carriers

202 e from 21 pg/mL pre-lipopolysaccharide to 54 pg/mL post-lipopolysaccharide, P<0.001.

203 R, 1045-4652] pg/ml vs 3372 [IQR, 1553-5452] pg/ml, respectively; P < .001), and lower admission-to-d

204 type natriuretic peptide) was elevated (5743 pg/mL).

205 ons of GDF-15 (median, 4225 [IQR, 3197-5972] pg/mL versus median, 2187 [IQR, 1344-3620] pg/mL, P<0.00

206 lysis revealed a 2C-DNA value of 3.8 +/- 0.6 pg (1Cx monoploid genome size 919.1 +/- 62.9 Mbp).

207 etic peptide [>40 pg/mL] or troponin T [>0.6 pg/mL]) were recruited, along with 61 age- and sex-match

208 e in the range 28.2 +/- 3.6 to 73.0 +/- 11.6 pg/mL after dilution.

209 chain at Week 78 (increases of 7.2 and 14.6 pg/ml for verubecestat versus 19.7 pg/ml for placebo, P-

210 red cells) and HbF per F-cell of 9.0 to 18.6 pg per cell.

211 (median [IQR]: 7.1 pg/ml [7.1, 7.1] vs 32.6 pg/ml [7.1, 88.0]; p = .001), MIP-1beta (30.7 pg/ml [30.

212 ml (interquartile range [IQR], 60.7 to 440.6 pg/ml), approximately threefold higher than the upper li

213 m had higher IL-1beta on days 3 (median +5.6 pg/mL; P = .007) and 7 (+10.9 pg/mL; P = .016).

214 (81.7 pg cm(-2) yr(-1)) and Kongsvegen (60.6 pg cm(-2) yr(-1)), and at Austfonna, but not at Holtedah

215 ioactive adrenomedullin (n = 2,003) was 66.6 pg/mL (34.6-136.4 pg/mL) and the median Simplified Acute

216 Furthermore, the mean bias of 7.6 pg/mL determined by Bland-Altman analysis, showed good a

217 compared with those in control (69.9 +/- 9.6 pg/ml vs 25.4 +/- 5.3 pg/ml, p = 0.0001) and the serum l

218 th geometric mean differences of -435 and -6 pg/ml, respectively (p = 0.0005).

219 occal enterotoxin B (SEB) as a model up to 6 pg/mL at the dynamic range of 3.5 orders with minimal sa

220 1)) and total toxin in suspension (4 x 10(6) pg.L(water)(-1)) obtained at an early phase of the bloom

221 e (enrollment criteria plus NT-proBNP <1,600 pg/ml), consisted of 245 patients followed-up for 6 mont

222 peptides: BNP >=150 pg/mL or NT-proBNP >=600 pg/mL (for patients with HF hospitalization within 12 mo

223 al cardiopulmonary resuscitation, 240 +/- 61 pg/mL; CO-E-CPR, 89 +/- 26 pg/mL; p < 0.05) and heme oxy

224 ted with 125 pg DNA (95.12% of alleles at 62 pg),; and we found 100% concordance over 5 common STRs w

225 thalates (6431 pg/g f.w.) and parabens (6234 pg/g f.w.).

226 owed a limit of detection of 0.26 IU/mL (624 pg/mL) and 14 ng/mL for IgE and IgG antibodies, respecti

227 s had lower NPTX2 concentrations (median 643 pg/mL, IQR (301-872)) than presymptomatic carriers (1003

228 g f.w.), far below those of phthalates (6431 pg/g f.w.) and parabens (6234 pg/g f.w.).

229 ntration in the aerosols accounted for 49-69 pg.L(air)(-1).

230 s, OPFRs, and nBFRs were 210, 25 000, and 69 pg/m(3) in indoor air, and 49, 670, and 110 ng/g in wris

231 allele carrying higher ADA risk (mean: 2,693 pg/ml) than for the other genotypes (mean: 2,317 pg/ml;

232 cells (ca. 4-6 million molecules or 0.5-0.7 pg protein per cell; based on our in-house developed NPM

233 cantly, either (mean absolute difference 0.7 pg/ml; intraindividual variation below 0.2%).

234 tivity and low limit of detection (LOD) (1.7 pg mL(-1)) allowed the direct determination of the targe

235 s with a median renin concentration of 172.7 pg/ml (interquartile range [IQR], 60.7 to 440.6 pg/ml),

236 L; P < 0.01), interleukin-6 (233.9 vs. 174.7 pg/mL; P < 0.05), troponin (83.0 vs. 28.5 ng/L; P < 0.05

237 and 14.6 pg/ml for verubecestat versus 19.7 pg/ml for placebo, P-values >= 0.1).

238 g/ml [7.1, 88.0]; p = .001), MIP-1beta (30.7 pg/ml [30.7, 30.7] vs 243.3 pg/ml [30.7, 344.4]; p = .00

239 s dominated OCP flux at Lomonosovfonna (81.7 pg cm(-2) yr(-1)) and Kongsvegen (60.6 pg cm(-2) yr(-1))

240 and 1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 0.70 pg mL(-1)) with Polydopamine (pDA) modification, satisfy

241 RFA and in group 2 from 2256.64 +/- 1021.72 pg/ml to 1388.13 +/- 890.15 pg/ml at 1 day after first R

242 MP-8 PoC test result, and TREM-1 levels < 75 pg/mL (P < 0.05).

243 entify ~1000 proteins reliably using only 75 pg of tryptic peptides, representing a 10-100-fold sensi

244 had higher admission (3822 [IQR, 2413-7784] pg/ml vs 5546 [IQR, 3257-8792] pg/ml, respectively; P <

245 enin concentration (normal range, 2.13-58.78 pg/ml) was above the upper limits of normal in 194 of 25

246 bove the limits of detection of us-RDT (>793 pg/mL) and co-RDT in 29 (25%) and 24 (20%) of 118 patien

247 on for our electrochemical biosensor was 0.8 pg/mL for SARS-CoV-2, indicating very good sensitivity f

248 Interleukin-6 (-24.9 pg/mL vs 442.8 pg/mL; P = .032) concentrations increased among nonrespo

249 rleukin-6 (23.1+/-4.5 pg/mL versus 6.5+/-5.8 pg/mL; P<0.001) and chemokine (C-X-C motif) ligand 1 (19

250 fied their presence in insect tissues: 941.8 pg/g of 9,10-EpOME and 2,198.3 pg/g of 12,13-EpOME in fa

251 18.9 pg/mL]) and 3 (87.2 pg/mL [75.2 to 97.8 pg/mL]).

252 pg/mL [6-13]; p<0.0001) and non-carriers (8 pg/mL [6-11]; p<0.0001), and was higher in converters th

253 The ELISA (LOD = 8 pg/mL) showed excellent performance in recovery studies,

254 anied by an increase in median NT-proBNP (+8 pg/ml; p = 0.02).

255 n-converting carriers (19 pg/mL [17-28] vs 8 pg/mL [6-11]; p=0.0007; adjusted for age).

256 y, about 1 x 10(6) cells.L(-1) and 2 x 10(8) pg.L(water)(-1)) and incubated for 21 h-showed about 15-

257 a median difference of 52.2 (IQR 20.1-85.8) pg/mL p = 0.0006.

258 .98, 0.90 sensitivity 0.80 specificity at 80 pg/mL; ROAUC = 0.96, 95% CI 0.92-0.99, 96% sensitivity,

259 from the evaluation cohort (IL-6 level > 80 pg/mL and CRP level > 97 mg/L) both correctly classified

260 PCR alone as the reference method, BDG (>=80 pg/mL) had a sensitivity of 69.8%, specificity of 81.2%,

261 0.93, 90% sensitivity, 73.5% specificity (80 pg/mL).

262 -1) and the limit of quantification was 3.81 pg mL(-1).

263 < 0.001) and IGFBP-2 levels (51.86 vs. 68.81 pg/mL, p < 0.001) were elevated after bariatric surgery.

264 e found that a BNP threshold of more than 81 pg/mL best associated with Mayo 2004 stage and also best

265 (25th-75th percentiles, 9.6-20.4 ng/L), 811 pg/mL (386-1436 pg/mL), and 1661 pg/mL (1179-2427 pg/mL)

266 NT-proBNP concentration at baseline was 816 pg/mL (interquartile range [IQR], 332-1822) and 455 pg/m

267 0.99, 96% sensitivity, 80% specificity at 82 pg/mL, respectively).

268 69.3 pg/mL]) (P <0.01) than groups 2 (234.84 pg/mL [216.8 to 318.9 pg/mL]) and 3 (87.2 pg/mL [75.2 to

269 e) vs placebo for eotaxin-3 (-30.06 vs -0.86 pg/mL; P = 0.0008) and total IgE (-7.90 vs -1.86 IU/mL;

270 R, 2413-7784] pg/ml vs 5546 [IQR, 3257-8792] pg/ml, respectively; P < .001), higher discharge (1922 [

271 Median concentrations of DBDPE in air (88 pg/m(3)) and dust (6500 ng/g) significantly exceed those

272 tional sensitivity defined at 15% CV was 1.9 pg/mL.

273 3 (median +5.6 pg/mL; P = .007) and 7 (+10.9 pg/mL; P = .016).

274 PIM: BOP >0.25%, PD >4.5 mm, and RANKL >19.9 pg/site.

275 IMP: BOP >0.25%, PD >4.5 mm and RANKL <=19.9 pg/site; PIM: BOP >0.25%, PD >4.5 mm, and RANKL >19.9 pg

276 Interleukin-6 (-24.9 pg/mL vs 442.8 pg/mL; P = .032) concentrations increased

277 than groups 2 (234.84 pg/mL [216.8 to 318.9 pg/mL]) and 3 (87.2 pg/mL [75.2 to 97.8 pg/mL]).

278 gher in Fontan patients (8,875.4 +/- 3,336.9 pg/mL) versus the ASD group (1,663.6 +/- 587.3 pg/mL, p

279 ntly higher among patients in group-1 (521.9 pg/mL [428.5 to 569.3 pg/mL]) (P <0.01) than groups 2 (2

280 9]) compared with presymptomatic carriers (9 pg/mL [6-13]; p<0.0001) and non-carriers (8 pg/mL [6-11]

281 s 0.1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 1.91 pg mL(-1)), and 1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 0.70

282 Median NT-proBNP value was elevated (910 pg/mL), and right ventricular dysfunction was moderate/s

283 ated in NPs from patients with CRSwNP (27.93 pg/mg of tissue) and NPs from patients with AERD (61.03

284 decreased in group 1 from 1865.18 +/- 828.93 pg/ml to 145.72 +/- 119.27 pg/ml at 1 day after RFA and

285 between primary and reinfection (1958 vs 932 pg/mL, P = .0402).

286 assay imprecision CV was < 10% for high (942 pg/mL) and low (38.2 pg/mL) PTH concentration.

287 goxin), with a median NT-proBNP level of 960 pg/mL (interquartile range, 626 to 1531 pg/mL) in the di

288 Systemic GH (12.32 vs. 50.97 pg/mL, p < 0.001) and IGFBP-2 levels (51.86 vs. 68.81 pg

289 L (624-1358), p<0.001) and non-carriers (990 pg/mL (597-1373), p<0.001) (corrected for age).

290 Per log (pg/mL) of BMP5, the odds of having BE increased by 50%.

291 interval, CI) = 0.240 (0.178, 0.301) log10 (pg/ml), P < 0.001], suggesting putative neuronal injury.

292 rence (95% CI) = 0.251 (0.136, 0.367) log10 (pg/ml), P < 0.001].

293 aneously quantify up to 35 proteins with low pg/mL sensitivity.

294 - 138), and suppressed ghrelin (AUC0-90 min, pg/mL*min; control: -3,433 +/- 2,647; C12: -11,825 +/- 3

295 ever, trace levels of RGS11 (in the range of pg/mL) in serum samples make it difficult to quantify us

296 nder the curve: median (interquartile range) pg/mL: 3285 (1697-6179) vs 1290 (758-3719); P < 0.001 an

297 concentrations were in the following ranges (pg/m(3)): 0.5-37.7 (E(6)PCB), 0.006-0.724 (E(17)PCDD/F),

298 chieving high sensitivity and specificity (~ pg/mL), short assay time (~1 h), low consumption (~5 muL

299 both clinical and nonclinical samples in the pg/mL to low ng/mL range.

300 SARS-CoV-2 antigens (S1 and N proteins) with pg/mL level sensitivities in 40 min.